Thank you for your donation! Your payment is being processed. Please do not refresh or navigate away from this page.

diaTribe Musings 2021 No. 1 - Glucagon


Join us for the 6th Annual diaTribe Musings Panel Discussions

Thursday, May 13, 2021

Taking the Fear out of Low Blood Sugar: Next-Generation Glucagon

6:30-8:00pm EDT /3:30-5:00pm PDT 


While Glucagon has long been available to help insulin users recover from severe hypoglycemia, adoption of the powerful hormone has remained low. That continues to be true even after easier ways to use glucagon were introduced in 2019, which eliminated the older cumbersome mixing and dosing requirements. What is behind this reluctance? Is it lack of awareness or a fear of using it? Or does it involve issues of access, cost, and insurance coverage? New advances in glucagon have also led to greater exploration into other practical uses of this powerful hormone for achieving tighter blood sugar control. 

Join us for this exciting panel to learn about how next-generation glucagon can empower people living with diabetes by preparing them for emergency situations and giving them greater piece of mind. Panelists will also discuss what the future holds for glucagon in dual-hormone closed loop insulin delivery systems and for maintaining safe blood sugar levels during exercise.

Panel discussion with Q&A from 6:30-8:00pm EDT / 3:30-5:00pm PDT.  Join us one hour prior to the start of the panel, at 5:30pm EDT / 2:30pm PDT, and be part of the discussion in our community session room, hosted by our incredible community manager, Cherise Shockley!  Networking and Sponsor Expo Booths also open at 5:30pm EDT / 2:30pm PDT and will be available after the panel concludes.


Our highly-regarded speakers are Crystal Bowersox, Musician & Patient Advocate, Lilly Diabetes; Paul Edick, Chairman & Chief Executive Officer, Xeris Pharmaceuticals; David Kendall, Endocrinologist & Senior Global Medical Advisor – Metabolism, Zealand Pharma; and Steven Russell MD/PhD, Associate Professor of Medicine, Harvard Medical School. The panel will be moderated by diaTribe Founder Kelly Close.




Crystal Bowersox, Musician & Patient Advocate, Lilly Diabetes 

Crystal Bowersox, a northwest Ohio native currently calling Nashville home, has built her life around music.  Crystal’s love for music developed at an early age from a need to find peace in a chaotic world. For her, music was always the most effective form of catharsis, and she would play for anyone, anywhere. In her own words, “my guitar was an appendage. I couldn’t live without it.” Crystal moved to Chicago as a teenager, where she spent her days performing underground on subway platforms in between working odd jobs. While in the big city, she broadened her musical horizons and shared her talents with a variety of venues, ultimately auditioning for the ninth season of American Idol. Since her introduction to the world through television, Crystal has released two LP’s, two EPs, and several singles. Additionally, she has used her talents to benefit several causes close to her heart and has become an advocate and inspiration for people living with Type 1 Diabetes. Crystal has been recording and performing all while managing her diabetes. Knowing the importance of having a support network in place, she continues to advocate for people living with diabetes and inspire them to empower themselves and those around them.



Paul R. Edick, Chairman & Chief Executive Officer, Xeris Pharmaceuticals

Paul Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017. Prior to Xeris, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals and before that he was Chief Executive Officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company. Mr. Edick has extensive industry experience with leading consumer, pharmaceutical, and healthcare organizations, including Pharmacia and Searle Pharmaceuticals. He also has experience leading the US managed care organization, US marketing organization, and Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising, and advisory positions in Procter & Gamble, Ortho Pharmaceuticals, and The Hamilton Group. Mr. Edick has served on numerous pharmaceutical and healthcare company boards. Mr. Edick holds a Bachelor of Arts in psychology from Hamilton College. 



David Kendall MD, Endocrinologist & Senior Global Medical Advisor – Metabolism, Zealand Pharma

David M. Kendall, M.D., is a Senior Global Medical Advisor and a senior member of the Global Medical Affairs team at Zealand Pharma A/S.  In this role, Dr. Kendall brings his expertise in diabetes and metabolism - and his commitment to clinical care and treatment innovation – to support Zealand’s medical and scientific activities focused on the development and delivery of peptide-based therapies for metabolic, gastrointestinal and inflammatory diseases. Dr. Kendall has more than 30 years of experience in diabetes research, education, clinical care and pharmaceutical development.  His work has focused on the care and management of diabetes and its complications, and the treatment of cardiovascular, renal and metabolic diseases.  Prior to joining Zealand in August of 2020, he held leadership roles in clinical and academic medicine and the biopharmaceutical industry, including Chief Scientific and Medical Officer of the American Diabetes Association, Chief of Clinical Services and Medical director of the International Diabetes Center, and Associate Professor of Medicine at University of Minnesota. Dr. Kendall received his bachelor’s degree from St. Olaf College and his MD from the University of Minnesota Medical School.  He completed internal medicine residency training and diabetes and endocrine fellowship training at the University of Minnesota Medical School.



Steven Russell MD/PhD, Associate Professor of Medicine, Harvard Medical School; Massachusetts General Hospital Diabetes Research Center

Dr. Russell is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician at Massachusetts General Hospital. He completed MD/PhD training at University of Texas Southwestern Medical School and a residency in Internal Medicine and fellowship in Endocrinology at the Massachusetts General Hospital. He is board certified in Endocrinology, Diabetes & Metabolism. Dr. Russell was the principal clinical investigator of a collaboration between Massachusetts General Hospital and Boston University to develop a wearable bionic pancreas system for automated glycemic management in people with diabetes mellitus. The technology has been licensed to Beta Bionics, a public benefit corporation, for commercialization in the form of the iLet bionic pancreas. Dr. Russell is the Study Director for the ongoing iLet pivotal trials. His other projects include evaluation of continuous glucose monitoring technology, methods for automated management of glucose in hospitalized patients, investigations of methods to improve insulin pharmacokinetics, and investigations of stable formulations of glucagon. Dr. Russell’s research has been supported by the National Institutes of Health (NIH), The Leona M. and Harry B. Helmsley Charitable Trust, the Banting Foundation, the American Diabetes Association, and the Juvenile Diabetes Research Foundation. 



Kelly L. Close, Founder, The diaTribe Foundation & President, Close Concerns

Kelly is the founder and Chair of the Board of The diaTribe Foundation, a nonprofit dedicated to improving the lives of people living with diabetes and prediabetes, and advocating for action. Since 2006, she has been editor-in-chief at, our free website focused on making people with diabetes healthier, happier, and more hopeful. We send diaTribe mailers weekly to over 225,000 people with diabetes and their families. Since 2002, Kelly has been leading Close Concerns, a healthcare information firm focused on diabetes, obesity, digital health, and connected care. Each year Kelly and her colleagues attend over 40 scientific and regulatory gatherings in the US and around the world, focused in these areas; they read the key medical literature in the field and write regularly about dozens of private and public companies and nonprofit organizations in the field. Kelly graduated from Amherst College and Harvard Business School and lives in San Francisco with her husband and three children. Kelly's passion for diabetes comes from her extensive professional work as well as her personal experience living with diabetes for nearly 35 years.

About diaTribe Musings

Previously known as Musings Under the Moon, when it was a single live event at the ADA Scientific Sessions, diaTribe Musings is now one of The diaTribe Foundation's most treasured ongoing virtual programs, engaging a diverse audience in thought-provoking dialogue and providing an opportunity to connect healthcare providers, business leaders, people with diabetes, advocates, families, entrepreneurs, and policymakers. Musings tickets are complimentary thanks to the generous support of our sponsors. We welcome anyone interested in learning about the massive shifts and opportunities occurring in the world of diabetes. Please spread the word and share this event with anyone interested in learning more about diabetes. Join the conversation on Twitter with #diaTribeMusings.

Past Musings Events

September 1, 2020

Coverage of all past Musings events in diaTribe Learn


Thank you to our sponsors for making this event possible


Presenting Sponsor


Gold Sponsor


Silver Sponsors





How You Can Join Us

Sign Up For diaTribe Updates!

We will never sell your data and we promise to keep your details safe and secure. For more information see our privacy policy.